Equities research analysts expect Natera Inc (NASDAQ:NTRA) to report sales of $72.03 million for the current quarter, Zacks reports. Three analysts have made estimates for Natera’s earnings. The lowest sales estimate is $70.30 million and the highest is $74.20 million. Natera reported sales of $53.80 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.9%. The business is expected to issue its next earnings results on Tuesday, March 12th.

According to Zacks, analysts expect that Natera will report full-year sales of $262.98 million for the current year, with estimates ranging from $258.50 million to $268.69 million. For the next fiscal year, analysts forecast that the company will report sales of $329.35 million, with estimates ranging from $307.90 million to $339.87 million. Zacks’ sales averages are an average based on a survey of analysts that follow Natera.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.03). Natera had a negative net margin of 58.00% and a negative return on equity of 752.93%. The company had revenue of $65.30 million for the quarter, compared to analyst estimates of $66.42 million. During the same quarter in the prior year, the business earned ($0.51) EPS. Natera’s revenue was up 16.8% compared to the same quarter last year.

A number of research firms recently commented on NTRA. JPMorgan Chase & Co. began coverage on shares of Natera in a research note on Friday, October 5th. They set a “neutral” rating and a $26.00 price objective on the stock. BidaskClub lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. TheStreet lowered shares of Natera from a “c-” rating to a “d+” rating in a research note on Tuesday, October 9th. Morgan Stanley raised their price objective on shares of Natera from $21.00 to $41.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. Finally, Zacks Investment Research lowered shares of Natera from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $28.25.

In other Natera news, insider Jonathan Sheena sold 166,667 shares of Natera stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $20.66, for a total value of $3,443,340.22. Following the transaction, the insider now owns 372,583 shares in the company, valued at $7,697,564.78. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Steven Leonard Chapman sold 45,000 shares of Natera stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $25.16, for a total transaction of $1,132,200.00. Following the completion of the transaction, the chief operating officer now owns 16,628 shares in the company, valued at approximately $418,360.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,014,988 shares of company stock worth $48,674,710. 13.18% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Northern Trust Corp boosted its stake in Natera by 1.5% in the 1st quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock worth $3,483,000 after purchasing an additional 5,428 shares during the period. Millennium Management LLC boosted its stake in Natera by 218.7% in the 1st quarter. Millennium Management LLC now owns 316,222 shares of the medical research company’s stock worth $2,931,000 after purchasing an additional 216,987 shares during the period. Essex Investment Management Co. LLC acquired a new position in Natera in the 2nd quarter worth approximately $3,281,000. Fred Alger Management Inc. acquired a new position in Natera in the 2nd quarter worth approximately $33,271,000. Finally, Dupont Capital Management Corp acquired a new position in Natera in the 2nd quarter worth approximately $526,000. Hedge funds and other institutional investors own 67.46% of the company’s stock.

NASDAQ NTRA opened at $16.80 on Monday. Natera has a 12 month low of $8.60 and a 12 month high of $29.62. The company has a market cap of $1.26 billion, a P/E ratio of -7.00 and a beta of 2.11.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Intrinsic Value

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.